Cilnidipine, >=98% (HPLC), powder

Cilnidipine, >=98% (HPLC), powder

Application

Cilnidipine has been used:in cell viability assay of pheochromocytoma (nPC12) cellsin photoirradiation and photodegradation studies to understand effect on albuminuria in diabetic nephropathy

Biochem/physiol Actions

Cilnidipine is a slow-acting Ca2+ channel blocker; antihypertensive; vasodilator; dual blocker of L-type voltage-gated Ca2+ channels in vascular smooth muscle and N-type Ca2+ channels in sympathetic nerve terminals that supply blood vessels. Cilnidipine may offer an advantage over nifedipine as the long term intake of the latter has been linked to increased risk of myocardial infarction and mortality in patients with coronary artery disease. Cilnidipine lowers blood pressure, but has less effect on sympathetic activity. Unlike nifedipine, cilnidipine does not inhibit PKC.

Features and Benefits

This compound is featured on the Calcium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Packaging

Protect from high temperatures.

10, 50 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level InChI key InChI Manufacturer Solubility Form Assay Price Quantity
3573304 Cilnidipine, >=98% (HPLC), powder light yellow 100 KJEBULYHNRNJTE-DHZHZOJOSA-N 1S/C27H28N2O7/c1-18-23(26(30)35-14-8-11-20-9-5-4-6-10-20)25(21-12-7-13-22(17-21)29(32)33)24(19(2)28-18)27(31)36-16-15-34-3/h4-13,17,25,28H,14-16H2,1-3H3/b11-8+ SIGMA-ALDRICH DMSO: ≥20 mg/mL, H2O: ≤2 mg/mL powder ≥98% (HPLC)
£225.64 (exc VAT) per 10MG
-
+
3573305 Cilnidipine, >=98% (HPLC), powder light yellow 100 KJEBULYHNRNJTE-DHZHZOJOSA-N 1S/C27H28N2O7/c1-18-23(26(30)35-14-8-11-20-9-5-4-6-10-20)25(21-12-7-13-22(17-21)29(32)33)24(19(2)28-18)27(31)36-16-15-34-3/h4-13,17,25,28H,14-16H2,1-3H3/b11-8+ SIGMA-ALDRICH DMSO: ≥20 mg/mL, H2O: ≤2 mg/mL powder ≥98% (HPLC)
£800.89 (exc VAT) per 50MG
-
+